key: cord-0949237-01sxjp30
authors: Saini, Geetanjali; Swahn, Monica H; Aneja, Ritu
title: Disentangling the COVID-19 Health Disparities in African Americans: Biological, Environmental and Social Factors
date: 2021-02-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab064
sha: 61d7443ead9bdcb45b9b9defe4b290eaa1558550
doc_id: 949237
cord_uid: 01sxjp30

The stark racial disparities related to the COVID-19 pandemic in the U.S., wherein minority populations are disproportionately getting infected and succumbing to the disease, is of grave concern. It is critical to understand and address the underlying causes of these disparities that are complex and driven by interacting environmental, social and biological factors. In this article we focus on the AA community and examine how social and environmental determinants of health intersect with biological factors (comorbidities, underlying genetics, host immunity, vitamin D levels, epigenetics) to exacerbate risk for morbidity and mortality.

The stark racial disparities already observed in coronavirus disease 2019 in the US, utterly decry the view that the coronavirus is a great leveller. Put simply, Indigenous Americans, African Americans (AAs), Hispanic Americans, and Pacific Islander Americans are disproportionately getting infected and succumbing to the disease, causing grave concerns 1, 2 . There is a clear urgency for understanding and addressing the underlying causes of these disparities as the pandemic rages on. While more information is needed and substantive research has yet to be conducted to truly understand their causes, it is already evident that these disparities are complex and likely fuelled by interacting biological, environmental, and social factors.

In principle, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus affects the young and the elderly, the rich and the poor. When it comes to eliminating its human host though, the biases come to the fore; a higher mortality rate has been observed in older (>65y), immunocompromised patients and those with underlying disorders 3 . In the US, AAs have the second highest overall COVID-19 mortality rates which is 1.6 times higher than that of Whites and 2.4 times than that of Asians 2 . Currently (December 2020), AAs account for 18.5% of COVID-19-related deaths despite representing only 12.4% of the US population ( Figure 1A ). After adjusting for age, the data exposes an even larger gap in mortality rates, with AAs experiencing a 2.7 times higher mortality rate than Whites 2 ( Figure  1B) . Clearly, disparities are observed in all age brackets, and alarmingly, more young AAs are now succumbing to the disease. In New York City-one of the hardest hit, COVID-19 hot spots-the death rate in AAs is 360.2 per 100,000 versus 104.6 per 100,000 in Whites 2 . Similar disproportionate mortality rates M a n u s c r i p t 

The history of racial health disparities in the US is unfortunately long-standing and complex. The reasons for inequity are multifactorial and have been a subject of extensive debate and research. There is already a call for a National Commission on COVID-19 Racial and Ethnic Disparities 6 and efforts by scientists to debunk the myth of black immunity to the virus. Herein, we outline the so far noted factors that seem most closely related to the health disparities within COVID-19. We begin by discussing the social and environmental factors that play a sizeable role in poorer disease outcomes in AAs. While these pertain to most minority groups in the US, our article is exclusively devoted to discussing factors responsible for health disparities in the AA community. The subsequent section spotlights possible biological factors that in conjunction with the social and environmental factors, may contribute in heightening the disparities in AAs. We also briefly discuss possible strategies to address these inequities.

The environmental and social factors that drive health disparities in the US are well documented and rooted in the current socioeconomic, environmental, and cultural conditions. These are often described as the social determinants of health. In fact, the social determinants of health framework is very helpful and highly relevant in terms of understanding and providing context to health disparities including those observed with COVID-19 7 . Typically the framework outlines five specific but intersecting domains: health and health care; economic stability; education; neighbourhood and the built environment; and social and community context. In the case of COVID-19, these social determinants of health may intersect with biological factors to exacerbate the risk of morbidity and mortality 8 .

In brief, there are several social determinants of health that may help to provide context to the COVID-19 disparities. Low socioeconomic status or lack of economic stability is often identified as a predominant factor underlying a range of health disparities. For example, 21% AAs compared to 9.1% Whites, live below the poverty line 9 . Lack of health insurance (11% AAs vs. 6% Whites were uninsured in 2017 10 ) or adequate health coverage, inequalities in access to healthcare, lack of primary care doctor as a point of contact, and lack of trust in the healthcare system, are all major impediments 11 . These factors have an immediate and substantial bearing on the racial disparities in COVID-19, as timely access to health resources, such as the emergency department and intensive care, is critical. However, there is also a disparity in preventative care being provided to AA populations, which significantly contributes to disparities in chronic health conditions found to increase risk of poor COVID-19 outcomes.

A recent review stated that the fundamental cause of the pandemic inequity in the US is racial capitalism 12 . It is indisputable that numerous well documented environmental characteristics pertaining to the neighbourhood and built environment as well as the social and community context, such as residential segregation, high-density residential areas, M a n u s c r i p t crowded living conditions, distance from grocery stores and medical facilities, neighborhood disadvantage and violence, and air pollution, exacerbate health inequities in the AA community 11 .

Air pollution is likely a critical environmental factor that increases susceptibility to COVID-19. A recent, unpublished report from Harvard University suggests that long-term exposure to PM2.5 can lead to an increase in the COVID-19 death rate in the US 13 . The impact of longterm air pollution, particularly on lung health, is well known. A strikingly large proportion of AAs live in the proximity of oil and gas refineries and other settings with high levels of air pollution. As such, their overall levels of exposure are generally higher, likely impacting their health more adversely than Whites 14, 15 .

Disadvantaged neighborhoods also create a whirlpool of stress, which is linked to a higher incidence of chronic diseases and inflammation, as well as an increased risk of mortality 11 . Intriguingly, a study reported that AA youths who were subjected to racial discrimination, expressed a higher prevalence of low-grade inflammation (indicated by elevated cytokine levels). Those who identified positively with their racial identities did not evince such an outcome 16 . Many of the neighborhood disadvantages or environmental factors are also considered social in nature and are often directly related to racism and discrimination, which clearly falls under the rubric of social determinants of health 17 .

Finally, at this moment in time, in the midst of the COVID-19 pandemic, it is very clear how systematic racism and disadvantage serve as underpinnings of both short and long term health inequities. Of particular concern with respect to minority health, is the limited access to preventative care, which may be the key driver for many of the chronic diseases that in turn exacerbate risk for COVID-19. In fact, there is a medical term for this, "acute on chronic" which refers to a longer term illness or medical condition which is aggravated by an acute illness and that the acute illness has worse health outcomes than it would have in the absence of the chronic illness or condition 18 . This is exactly what we have seen with the COVID-19 pandemic in minority communities already heavily burdened by chronic diseases such as cardiovascular diseases, cancers, diabetes and metabolic syndrome among others 18 . Obesity as a health condition is a key risk factor for COVID-19 and future research will likely provide a more specific determination of the risk levels. However, a recent study that simulated a hypothetical scenario using large national databases, found that eliminating both obesity and tobacco use in the U.S. population, would reduce disparities and result in greater health equity, demonstrating the need for prevention and access to preventative care 19 .

Ever since the Department of Health and Human Services published their "Action Plan to Reduce Racial and Ethnic Health Disparities: Implementation Progress Report 2011-2014 in 2015 20 , an ongoing focus on the multifaced approach required was outlined to recognize the need for: 1. Expanding access to quality health care, 2. Addressing diversity and cultural competence in the health care workforce, 3. Supporting population health, 4. Enhancing data collection and research. While there remains grave disparities that urgently need to be addressed, we also need to factor in that the infrastructure to address these disparities was M a n u s c r i p t put in place or elevated relatively recently. Within the past decade tremendous progress was made such as establishing Offices of Minority Health across several U.S. health agencies, elevating the National Center on Minority Health and Health Disparities as an Institute within the National Institutes of Health among other structural changes designed to specifically address minority health inequities 20 . However, the weaknesses and lack of integration across systems and health agencies, have severely worsened the impact of COVID-19 in minority communities and underscored the need for additional strategies and action.

As a multifaceted approach is required to address disparities in general, so is the engagement across sectors and an understanding of the factors that drive providers and payers in their decision making process for addressing health disparities 21 . The American Medical Association for example has made available a range of resources and training materials for physicians such as the "Health Disparities Toolkit" and the "AMA's Code of Medical Ethics" on their website 22 . It specifically states that they work to increase the number of minority physicians to ensure that they reflect the U.S. population, that they have made the elimination of racial and ethnic health disparities a top priority, and that they are working with physicians to recognize and manage low health literacy among their patients 22 . Similarly, the American Hospital Association is addressing health disparities specifically through innovative partnerships and the implementation of community health workers program as outlined on their website 23 . Despite these initiatives, concerns about inequity in treatments for COVID-19 have been made and reported in the news. As an example, an AA female physician, internist, recently and tragically died of COVID-19 several weeks after having raised concerns regarding the inadequate treatment received, which she determined was attributable only to her race 24 . However disturbing, social psychologists have outlined the disparities present in health care delivery, specifically regarding physician's implicit biases that may affect their decision making process regarding treatments and also implicit biases that may impact the physician-patient relationship which in turn may adversely impact communication 25 . The most practical strategy for addressing these biases is to accelerate the process of diversifying the work force and to enhance the cultural competency of health care workers 26 .

Priorities for reducing racial health disparities from academic scholars have also suggested that we should focus on "what we already know". In their powerful review, Williams and Cooper provides recommendations for developing communities of opportunities to mitigate the adverse impact of systematic racism, enhancing access to high quality care for all, particularly focusing on preventative care, and finally conducting research to identify the optimal strategies for building both political will and also support to address the social inequities in health, all of which have direct relevance for the COVID-19 pandemic in the U.S 27 .

But, perhaps it is that last point that was raised by Williams and Cooper, about ensuring the political will and support for addressing the social inequities in health, where we need to start. It seems that in many settings, the message around health disparities and social M a n u s c r i p t inequities in health have not been fully embraced or endorsed. As such, the message from the former Secretary of Health & Human Services, Kathleen G. Sebelius, remains a critically important communication strategy for the work ahead: "It is time to refocus, reinforce, and repeat the message that health disparities exist and that health equity benefits everyone" (Page 1. https://www.minorityhealth.hhs.gov/assets/pdf/hhs/HHS_Plan_complete.pdf).

In addition, there are a few key strategies that may prove helpful in the short term to stem the pandemic and its impact in minority communities. In particular, strategies that support COVID-19 testing, contact tracing and mitigating measures for community spread remain critically important factors to reduce the COVID-19 disparities.

Education and improved health literacy can play a fundamental role in tackling the already noted COVID-19 health disparities. The ability to obtain, process and understand basic health information is key to engaging in protective measures. It has already been noted that health literacy is an underestimated problem related to COVID-19 28 as it is of tremendous importance in supporting the public in taking precautions to limit exposure, assessing the value of information, making well-informed decisions, weighing the benefits and disadvantages of situations, comprehending the statistics that news articles may include, and knowing the specific strategies recommended for social distancing, frequent handwashing and wearing a mask and other key elements required to fight the pandemic. Additionally, the distribution of myths and misinformation have likely been a barrier in the response and uptake of necessary precautions. In particular, the early myths regarding AAs immunity to the virus 6 may have been particularly devastating in communities already experiencing stigma and mistrust of medicine and government 29 .

At the start of the pandemic, dangerous and baseless rumours about how AAs were impervious to the disease were circulating in some communities. Outreach community programs for minorities can help inform and rectify such misinformation, but in this regard, educational interventions seem to be falling short. Education and health literacy initiatives can also be a great complement to awareness in determining a successful strategy to fight the disease. Unfortunately, only 22% of AAs compared with 36% of non-Hispanic Whites complete four years of college 30 , a factor that needs to be considered when designing new strategies that is also recognized by the American Medical Association in the training and support of physicians (https://www.ama-assn.org/). Social distancing is an effective way to stymie the spread of the highly contagious coronavirus. However, a high proportion of AAs are employed in essential services and industries (e.g., healthcare, transportation, grocery stores/supermarkets, public transit, burial services) where exposure to the virus is high, social distancing strategies difficult to implement, and options for working remotely are absent. Similarly, because of the living conditions and lower socioeconomic status, minorities are more heavily reliant on public transportation for commuting to and from work 31 which further exacerbates the risk of M a n u s c r i p t exposure to the virus. Similarly, wearing protective gears has been highly recommended and is required in some states. However, because of the racial profiling and racism, some minorities, in particular AA men, are reluctant to wear face masks, fearing for their safety, particularly when visiting retail stores 32 . These issues underscore the underlying causes of health disparities and the need for broader, cross-cutting prevention strategies that reflect cultural context, racism, and structural inequities.

Although SARS-CoV-2 is a close relative of the SARS-CoV virus, they are markedly different in their biology and epidemiological dynamics 33 , with the COVID-19 disease pathology appearing to be distinct and challenging in several ways. One of the commonalities is that people above the age of 60 or those with underlying conditions, are at higher risk of developing severe complications after infection with either virus 34, 35, 36 . Data from COVID-19 patients show poorer clinical outcomes (admitted to ICU, invasive ventilation, or death) in patients having at least one of the following comorbidities: hypertension, diabetes, obesity, chronic metabolic disease, chronic obstructive pulmonary disease (COPD), cardiovascular or cerebrovascular diseases, hepatitis B infections, chronic kidney disorders, malignancy and immunodeficiency [36] [37] [38] [39] [40] . According to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases, diabetes, chronic lung disease and obesity are the most frequently reported underlying medical conditions in hospitalized COVID-19 patients. This may largely explain why the AA community is so badly hit by the pandemic, since AAs exhibit a higher incidence of comorbidities, including cardiovascular diseases and diabetes 41, 42, 43 . A compromised innate immunity and pro-inflammatory state in patients with diabetes can increase susceptibility to cytokine storms and thrombotic events that are characteristic severe COVID-19 outcomes 44 . Additionally, COVID-19 itself can worsen glucose control in diabetics thus whipping up a vicious cycle 448 .

Patients with asthma are also considered high risk 45 . The AA population bears a greater burden of asthma compared with White Americans 46 . The high pollen season that coincided with the COVID-19 pandemic in the US, can cause allergy flare-ups and trigger, or aggravate asthma 47 .

Obesity is associated with several comorbidities including asthma, cardiovascular disorders and type II diabetes 48, 49 . Among different racial groups, the highest prevalence of obesity has been observed in non-Hispanic Blacks and could be one of the factors resulting in a higher incidence of comorbidities in this population 50 .

The cancer burden in AAs is also disproportionately high compared with other racial and ethnic groups in the US. After cardiovascular disorders, cancer is the second cause of death in AAs 51 . More specifically, prostate, breast, lung, and colorectal cancer are the most M a n u s c r i p t commonly diagnosed malignancies in this group 51 . The rates of lung cancer in AA males is 15% higher than in white males (although 14% lower in AA women vs white women) 515 . This sex difference is largely attributed to differential smoking patterns. Cigarette smoking is linked to chronic inflammation, which can lead to COPD, lung cancer and other lung diseases 52 . Although overall tobacco use is not higher among AAs (compared to Whites), studies suggest that AAs are more vulnerable to the damaging effects of smoking 53, 54, 55 .

The genetic composition of humans has been greatly influenced by co-existing microbes. Some of the medical conditions that AAs are predisposed to have a genetic basis. For example, malaria-causing Plasmodium species are an evolutionary driving force selecting for advantageous genetic traits that proffer protection against the dreaded disease. Certain polymorphisms, such as those causing sickle cell disease (SCD), Glu-6-phosphatase deficiency, and beta-thalassemia, are prevalent in African populations (and other malariaendemic regions), and have been selected as they protect against severe forms of malaria 56 . In the US, SCD occurs in approximately 1 out of 365 Black/AAs, and 1 in 16,300 Hispanic-Americans 57 . The sickle cell trait (SCT; carrying one allele) occurs in about 1 in 13 Black/AAs 58 . The majority of SCD patients display lung function abnormalities, including asthma and hypoxemia 58 . It has been observed that people with SCD who were infected with seasonal Influenza or H1N1 developed more severe complications (acute chest syndrome, mechanical ventilation requirement) 59, 60 . It is too early to gauge the impact of SCD on COVID-19 prognosis, but those with SCD could potentially be at higher risk. These observations may have prompted the Harvard Medical School's Coronavirus Resource Center to add SCD in the updated list of conditions that could lead to severe COVID-19 symptoms 61 . Although individuals with SCT typically show no symptoms, they can experience SCD complications under certain circumstances such as under conditions of increased pressure or low oxygen in the atmosphere (as in altitude sickness) 62 . These conditions are simulated in the lungs of patients with COVID-19, whose clinical manifestations are very heterogeneous, ranging from pneumonia to acute respiratory distress syndrome (ARDS), hypoxemia and atypical symptoms resembling those observed at high altitudes 63, 64 . Therefore, individuals with SCT may experience severe COVID-19 symptoms. This nascent connection is worth exploring when sufficient clinical data is available. It is also of interest to determine if the preponderance of SCD and SCT in AAs may explain the observed racial disparity in COVID-19 outcomes.

Another interesting feature of malaria is that it may also be exerting a selective pressure in AAs. The hormone Angiotensin II (Ang II) is a major regulator of blood pressure and its concentration is determined by angiotensin-converting enzyme (ACE) and angiotensinconverting enzyme 2 (ACE2). Gene polymorphisms in ACE (e.g., I/D polymorphism in intron 16) 65 and ACE2 66 lead to higher levels of Ang II and hypertension, and are suggested to confer protection against severe malaria 67 . These polymorphisms have been linked to populations in malaria-endemic regions, including Africa 67, 68 . The incidence of hypertension in AAs (>45%) 69 is higher than other groups, and its genetic basis can, in part, be attributed to these polymorphisms 70 . Despite conferring a protective role against malaria, these M a n u s c r i p t polymorphisms increase the risk of other illnesses and possibly severe COVID-19 related complications. Interestingly, the ACE (I/D) polymorphism has also been associated with type 2 diabetes 71 , and obesity 72, 73 and is also considered a risk factor for ARDS mortality 74 . A comprehensive large-scale study of the prevalence of these polymorphisms in AAs is required to elucidate their contribution to hypertension and other comorbidities that enhance susceptibility to COVID-19.

Microbial pathogens can also shape differential ancestry-related immune response to infections 75 . Compared to Whites, AAs are significantly more likely to carry genetic variants of pro-inflammatory cytokines 76, 77 . Compounding this effect is the observation that they also carry genotypes known to down-regulate the anti-inflammatory response, including variants of IL-1, IL-6, IL-10 and TNF-α 76 . This may explain why a higher proportion of inflammatory diseases strike the AA community 78 . Chronic inflammation is also the underlying cause of several diseases (e.g., cardiovascular disorders, diabetes, obesity, kidney ailments, and cancer) that are more frequent in AAs than in Whites. In addition to inflammatory responses, marked differences in antiviral responses have also been observed among populations 75 and are of considerable significance, since a subset of COVID-19 patients with severe symptoms develop a "cytokine storm", wherein the body mounts an "overenthusiastic" response to the invading virus. Cytokine storm is a type of systemic inflammatory response caused by proinflammatory cytokines that attack the host tissues (primarily the lungs), thereby leading to pneumonia and hypoxemia 79 .

Mounting evidence shows that COVID-19 is also associated with distinct coagulation abnormalities (e.g., thrombotic events and elevated levels of D-dimer, von Willebrand Factor (vWF), and Factor VIII), which may cause complications in severe cases 80 . COVID-19 autopsies have revealed abnormal clotting in multiple organs and the presence of megakaryocytes and platelet-rich thrombi in the lungs, heart, kidneys, and liver 81 . These findings are particularly alarming because a prothrombotic state may start early on in the disease course; it has been observed even among younger patients, and can occur despite anticoagulation therapy. In COVID-19 survivors, coagulation abnormalities may cause longterm complications of the heart, brain, and lungs. Abnormal blood clotting can cause multiorgan failure, strokes, various neurological conditions (e.g. dizziness, headaches, seizures, brain fog, loss of smell and taste), hypoxia, pulmonary embolism, and arterial thromboembolism, deep vein thrombosis and mortality 80 . It has been established that uncontrolled or hyperactive host immune responses triggered by the virus contribute to disease severity in COVID-19 patients. A recent study reported that in a subset of patients, sustained and systemic activation of the complement pathways, a key component of the innate immunity, may be resulting in microvascular injury and thrombosis 82 . The risk factors for abnormal coagulation include older age, being male, diabetes, and obesity.

Abnormal coagulopathy, reflected by elevated levels of D-dimer, vWF and Factor VIII, is fast emerging as a crucial marker of disease severity and mortality in COVID-19 patients, and calls for an investigation into racial differences, if any, in the molecular and genetic nature of blood clotting. D-dimer is a degradation product of fibrin, and elevated D-dimer levels is A c c e p t e d M a n u s c r i p t indicative of presence or risk of thrombotic events 83 . vWF is an essential component of the blood clotting system and is produced in endothelial cells and megakaryocytes. Elevated levels of vWF may indicate endothelial injury and an increased risk of thrombosis. It has been suggested that hypercoagulopathy and respiratory distress in COVID-19 patients may, in part, be due to a vWF dependent mechanism 84 . Similarly, a high level of Factor VIII, an essential blood coagulation factor is a marker of increased risk of deep vein thrombosis and pulmonary embolism 85 . A comparison of platelet function and transcriptome between healthy AAs and Whites has shown that the molecular route of blood clotting differs between the two racial groups 86 . This may also partly explain the differences in heart disease incidence and outcomes between AAs and Whites. Studies have also shown that AAs have higher levels of D-dimer, vWF and Factor VIII compared with Whites and Hispanics. The higher levels of these markers in AAs are due to both genetic and environmental factors 87, 88, 89 , and may contribute to severe COVID-19 outcomes. Plasma D-dimer levels are higher in AAs than Whites even among hypertensive patients 90 . Thus, it is probable that even within high-risk groups with underlying heart conditions, ethnic disparities in COVID-19 outcomes may be observed.

Chronic D hypovitaminosis is associated with increased risk of respiratory tract infections, including pneumonia and ARDS, apart from several comorbidities (e.g. obesity, diabetes, hypertension) [91] [92] [93] [94] .Vitamin D deficiency may increase the risk of severe COVID-19. There is strong evidence supporting the link between vitamin D deficiency and mortality in AAs and European populations 91, 92, 95, 96 . Vitamin D deficiency is disproportionately higher in AAs (estimated at 76%) and may contribute to the higher rates of COVID-19 infection and mortality in the AA population 96 . Furthermore, individuals aged over 50 often have lower vitamin D levels which may, in part, explain the high numbers of elderly succumbing to the infection 97 . Vitamin D is thought to reduce the risk of infection by attenuating inflammatory responses (e.g., cytokine storm in COVID-19 patients) and lowering viral replication rates 91, 92 . The impact of vitamin D supplementation on the COVID-19 disease course is currently being investigated in a multicenter randomized and controlled clinical trial (CoVitTrial 98 ).

Continuous social and environmental assaults lead to stress, inducing chronic inflammation, and ultimately the development of various diseases (e.g., obesity, diabetes mellitus, cancer, and cardiovascular diseases). Stress activates the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis which release chemical mediators of inflammation (CRP, IL-6, NF-κB, TNF-α) 11 . Environmental factors, including diet, smoking, pollution, and neighborhood characteristics, affect epigenetic modifications, thereby increasing or decreasing the susceptibility to various diseases. DNA methylation, histone modifications, and alterations in the expression of non-coding RNAs form the molecular basis of the epigenetic regulation of gene expression. Each environmental factor can establish a unique epigenomic imprint with potentially long-lasting or even trans-generational impact 99 .

A growing body of research have also outlined the transgenerational effects specifically of racism, described as the psychophysiological inheritance across generations in response to white dominance. Alternatively, it has also been described as inheriting racist disparities in A c c e p t e d M a n u s c r i p t health. There are new studies demonstrating the biological underpinnings of these health disparities, many of which can be directly attributed to racism. For example, a recent study using national longitudinal data, demonstrate upwardly mobile AAs were more likely to experience both acute and chronic discrimination compared to those not upwardly mobile, raising important questions about social context and environment as well as for epigenetics 100 . Similarly, while research is emerging across health topics, researchers have questioned whether epigenetics can serve to explain how differential environmental exposure may manifest in observed racial differences in chronic pain 101 . Similarly, research indicate that altered DNA methylation patterns are linked to age-associated health disparities for AAs. Epigenetics have been used to examine a range of health conditions among AAs including renal function, metabolic syndrome and cardiovascular health [102] [103] [104] [105] [106] ,

Both biological and non-biological factors appear to contribute to racial disparities in COVID-19. Large, multicentre, comprehensive clinical studies are warranted to elucidate the biological impact of each of these factors. Bio-banking COVID-19 patient samples is foundational and crucial to enable the conduction of such studies. It is abundantly clear that COVID-19 cannot be treated with a "one size fits all" approach. The identification of immunological and metabolomic differences among genetically diverse groups throughout the disease course will provide further insight into the biological underpinnings of COVID-19 disparities. For instance, susceptibility to the virus and disease severity could be affected by variations in the human leukocyte antigen (HLA) complex. Proof-of-concept studies are required to determine the role of HLA variants in infection, susceptibility and disease outcomes, as HLA subtyping could aid in early patient stratification. Although an HLA susceptibility map for SARS-CoV-2 has already been developed using in silico analyses 107 , these results need to be verified in clinical samples.

The SARS-CoV-2 enters the host cells upon binding to cellular receptors (e.g. ACE2) via its spike (S) proteins, and S protein priming by host serine proteases including transmembrane protease serine 2 (TMPRSS2) 108 . Evaluation of the genetic variants of these host factors within, and across populations, can be invaluable in identifying individuals and populations more susceptible to the virus and likely to have worse outcomes. A few studies have begun to determine genetic variants of ACE2 that can impact its expression and its enhanced or disruptive interactions with the virus along with effects on tissue specific expression 109, 110, 111 . Studies are also underway to identify polymorphisms that alter TMPRSS2 expression and its protease activity [109] [110] [111] [112] . Thus far, there appears to be significant variability in genetic determinants of these host factors' expression among individuals and populations. One study found that African populations are genetically predisposed to lower expression of ACE2 and TMPRSS2 and may therefore, be less susceptible to the coronavirus 111 . In contrast, the findings of another study suggest that AAs are likely more susceptible to the virus due to a commonly observed polymorphism in the androgen receptor (AR) gene 112 . AAs often carry a lower number of CAG repeats in the AR gene 113, 114, 115 leading to higher AR levels 116 . The TMPRSS2 promoter contains an androgen response element, which induces TMPRSS2 transcription upon AR activation 117 . Additionally, androgens have been shown to increase ACE2 activity in males 118 , which may explain the racial and gender disparities in COVID-19 infection and outcomes. It must be noted, however, that these M a n u s c r i p t contradictory reports lack clinical validation. As more clinical samples from COVID-19 patients become available, the relevance of ACE2 and TMPRSS2 polymorphism in racial disparities in COVID-19 warrants further study. Several promising drugs (both repurposed and new) and vaccine trials are underway. However, AAs and other minorities remain under-represented in clinical trials 119 . Considering that differences in the immune landscape among racial/ethnic groups can impact drug and vaccine potency/antigenicity, dosage, and side effects, it is crucial to ensure a balanced cohort composition in clinical studies. Additionally, the identification of the differences in the lung microbiome among different demographic subgroups is critical, since the human microbiome can profoundly affect host immune response, secondary bacterial infections, and drug efficacy. Several public opinion surveys make it plain that AAs are reluctant to get the COVID-19 vaccine, reflecting their continued mistrust in the medical system and the pharmaceutical industry, that finds its origins in the Tuskegee study and the Hela cell line research in the past. This pattern is in line with CDC's analysis of flu coverage data which shows that AAs are less likely than Whites and Asians to get vaccinated 120 .

To address these barriers, largely stemming from lack of data and integrated research that examine the intersection of the socioecological context, human behaviour and biological factors, new rigorous mixed-methods studies need to be conducted. As the pandemic evolved so rapidly, the need for new data created a surge of research that either examined clinic samples or that involved community surveys. These studies have helped us greatly by providing a wealth of data. Many strategic projects also capitalized on existing infrastructure to expand projects already underway in clinical settings or communities. But, in order to drive the science forward to better understand these disparities, studies that link clinical data, biological specimens with survey data will be of critical importance.

As mentioned earlier, the social determinants of health play a significant role in the transmission of COVID-19, its manifestation as well as treatment outcomes. As such, multiple data sources reflecting both biological samples, patient data and clinical records will be key. Previous studies have been well executed with similar goals and can serve as examples for future research such as the Dallas Heart Study for cardiovascular disease 121 .

COVID-19 is a novel, rapidly evolving disease, with unprecedented scale and ferocity, and for which the unknowns far exceed the knowns. The pandemic is nothing short of a siege, since, in a very short span of time, it has exacted a heavy human and economic toll. In the US which is in the throes of the ravaging pandemic, a searing image of racial disparity has emerged-the pandemic is a rattling wake-up call for the nation. Addressing health disparities will require sweeping reforms in the health care system, and public health infrastructure, as well as addressing structural inequities. Moreover, we need to provide M a n u s c r i p t better education to our students and substantially improve health literacy across all population groups.

In this review, we have presented a list of key biological factors that, individually or in combination with environmental and social factors, may elucidate the underlying pathways responsible for the grave disparities noted so far (Figure 3) . Meanwhile, there is an urgent need for our communities to come together and confront these alarming disparities. M a n u s c r i p t Funding This study was supported by a grant from the National Cancer Institute at the National Institute of Health (R01 CA169127) to RA.

The authors declare no conflicts of interest.

This study does not include factors necessitating patient consent.

Racial disparities in exposure, susceptibility, and access to health care in the US H1N1 influenza pandemic

Pandemic influenza planning in the United States from a health disparities perspective

The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. J Racial Ethn Health Disparities

Social Determinants and COVID-19 Disparities: Differential Pandemic Effects and Dynamics

Impact of Social Determinants of Health on the Emerging

Pandemic in the United States

Income and Poverty in the United States: 2017. Current Population Reports P60-263

Insurance Status and Racial Disparities in Cancer-Specific Mortality in the United States: A Population-Based Analysis

Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link

Racial Capitalism: A Fundamental Cause of Novel Coronavirus (COVID-19) Pandemic Inequities in the United States

Exposure to air pollution and COVID-19 mortality in the United States: A nationwide cross-sectional study. medRxiv

Discrimination, racial identity, and cytokine levels among African-American adolescents

Public Health's Approach to Systemic Racism: a Systematic Literature Review

Would the elimination of obesity and smoking reduce U.S. racial/ethnic/nativity disparities in total and healthy life expectancy?

Making the Case for Addressing Health Disparities: What Drives Providers and Payers? Health Equity

Reducing Racial Health Care Disparities: A Social Psychological Analysis

Addressing health and health-care disparities: the role of a diverse workforce and the social determinants of health

Reducing Racial Inequities in Health: Using What We Already Know to Take Action

COVID-19: health literacy is an underestimated problem. Lancet Public Health

Racial Minorities' Trust in Government and Government Decision makers

Educational Attainment in the United States: 2017. Table 1. Educational Attainment of the Population 18 Years and Over

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

SARS: prognosis, outcome and sequelae

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19 in Italy: momentous decisions and many uncertainties

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Ethnic distinctions in the pathophysiology of type 2 diabetes: a focus on black African-Caribbean populations

Diabetes in African Americans

COVID-19 and diabetes mellitus: An unholy interaction of two pandemics

Cancer statistics for African Americans

Chronic obstructive pulmonary disease and lung cancer

Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease

Smoking patterns in African Americans and whites with advanced

Sickle cell anaemia and malaria

Lung Function Abnormalities in Sickle Cell Anaemia

Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease

COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med

Acute Respiratory Distress Syndrome

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women

Gene polymorphisms in angiotensin I converting enzyme (ACE I/D) and angiotensin II converting enzyme (ACE2 C-->T) protect against cerebral malaria in Indian adults

Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: A meta-analysis and systematic review

Heart Disease and Stroke Statistics-2020 Update: A Report From the

The High Blood Pressure-Malaria Protection Hypothesis

Association of angiotensin converting enzyme gene (I/D) polymorphism with hypertension and type 2 diabetes

A meta-analysis of the association between angiotensin-converting enzyme insertion/ deletion gene polymorphism and the risk of overweight/obesity

Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population

ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS

Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations

Differential distribution of allelic variants in cytokine genes

African Americans and White Americans

Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens

The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease

COVID-19: consider cytokine storm syndromes and immunosuppression

Hematolological Manifestations of COVID-19: From Cytopenia to Coagulopathy

Megakaryocytes and platelet-fibrin thrombi characterize multiorgan thrombosis at autopsy in COVID-19: A case series

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Fibrin fragment D-dimer and the risk of future venous thrombosis

Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19

Elevated factor VIII levels and risk of venous thrombosis

Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c

Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study

Genetic regulation of plasma von Willebrand factor levels in health and disease

Von Willebrand factor and endothelial damage: a possible association with COVID-19. Ecological genetics

African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19

Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)

The Role of Vitamin D in Diabetes and Cardiovascular Disease: An Updated Review of the Literature

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

The problems of vitamin d insufficiency in older people

Epigenetics and Inflammatory Markers: A Systematic Review of the Current Evidence

Racial disparities in health among nonpoor African Americans and Hispanics: The role of acute and chronic discrimination

Could epigenetics help explain racial disparities in chronic pain?

Epigenetic markers of renal function in african americans

Epigenome-wide association study of metabolic syndrome in African-American adults

Epigenetics and the embodiment of race: developmental origins of US racial disparities in cardiovascular health

The Epigenome: On the Transgenerational Effects of Racism. The Physiology of Sexist and Racist Oppression

Inheriting Racist Disparities in Health: Epigenetics and the Transgenerational Effects of White Racism

Human leukocyte antigen susceptibility map for SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations

Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19?

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status

Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer

The CAG and GGC microsatellites of the androgen receptor gene are in

A c c e p t e d M a n u s c r i p t